Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + carboplatin + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
nab-paclitaxel + carboplatin + gemcitabine is a combination chemotherapy regimen evaluated as a neoadjuvant treatment for patients with locally advanced, muscle-invasive bladder cancer. The regimen includes ABI-007 (nab-paclitaxel), which is an albumin-bound nanoparticle formulation of paclitaxel designed to enhance drug delivery to tumors via albumin receptor-mediated transport while avoiding the toxicities associated with conventional paclitaxel solvents like Cremophor EL. This is combined with carboplatin, a platinum-based antineoplastic agent that induces DNA cross-linking, and gemcitabine, a nucleoside analog that inhibits DNA synthesis. The University of Michigan Rogel Cancer Center conducted a Phase 2 trial to assess the safety and efficacy of this triplet combination prior to radical cystectomy in patients whose cancer has invaded the bladder muscle wall.
- Other names
- ABI-007 + carboplatin + gemcitabinenanoparticle albumin-bound paclitaxel + carboplatin + gemcitabine
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + carboplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + carboplatin + gemcitabine.